Hemangeol

Thyroid Crisis, Atrial Fibrillation, Migraine + 23 more

Treatment

5 FDA approvals

20 Active Studies for Hemangeol

What is Hemangeol

Propranolol

The Generic name of this drug

Treatment Summary

Propranolol is a medication used to treat high blood pressure and other conditions. It is a mixture of two different chemical compounds, with one of them being about 100 times more powerful in binding to beta adrenergic receptors. Propranolol was first approved by the FDA in 1967.

Inderal

is the brand name

image of different drug pills on a surface

Hemangeol Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Inderal

Propranolol

1967

471

Approved as Treatment by the FDA

Propranolol, also known as Inderal, is approved by the FDA for 5 uses including Obstructive Hypertrophic Cardiomyopathy and Tremor, Essential .

Obstructive Hypertrophic Cardiomyopathy

Tremor, Essential

Helps manage Tremor, Essential

Essential Tremor

Helps manage Tremor, Essential

Cardiomyopathy, Hypertrophic

Hypertensive disease

Used to treat High Blood Pressure (Hypertension) in combination with Hydrochlorothiazide

Effectiveness

How Hemangeol Affects Patients

Propranolol is a drug used to treat high blood pressure. It lasts for a long time, so it is usually taken once or twice per day, depending on the patient's needs. If the patient suddenly stops taking propranolol, they may experience chest pain and heart attacks.

How Hemangeol works in the body

Propranolol works by blocking the effect of beta-adrenergic receptors. This causes the blood vessels to constrict, reduces the growth of new blood vessels, and encourages the death of endothelial cells. It also reduces the activity of the renin-angiotensin-aldosterone system.

When to interrupt dosage

The measure of Hemangeol is contingent upon the diagnosed ailment, such as Catecholamines, Hypertensive disease and Hemangiomas. The quantity of dosage is contingent upon the mode of delivery (e.g. Solution - Oral or Capsule, extended release - Oral) featured in the table below.

Condition

Dosage

Administration

Adrenergic Alpha-Antagonists

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Heart Attack

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Tachyarrhythmia caused by Digitalis intoxication

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Psychomotor Agitation

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Tremor

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Thyrotoxicosis

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Chest Pain

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Supraventricular Arrhythmias

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Hemangioma

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Cardiomyopathy, Hypertrophic

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Proliferating Infantile Hemangioma

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Hypertensive disease

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Performance Anxiety

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Pheochromocytoma

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Ventricular Tachycardia

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Migraine

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Gastroesophageal variceal hemorrhage prophylaxis

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Catecholamines

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Migraine Disorders

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Atrial Fibrillation

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Warnings

Hemangeol has fifteen contraindications, so it should be avoided in cases where any of the conditions in the table below are present.

Hemangeol Contraindications

Condition

Risk Level

Notes

Heart Decompensation

Do Not Combine

Bronchial Spasm

Do Not Combine

Asthma

Do Not Combine

Infants Weighing <2kg

Do Not Combine

Low Blood Pressure

Do Not Combine

Sick Sinus Syndrome

Do Not Combine

Asthma

Do Not Combine

Pheochromocytoma

Do Not Combine

Atrioventricular Block

Do Not Combine

Slow Heart Rate

Do Not Combine

Shock, Cardiogenic

Do Not Combine

Heart Decompensation

Do Not Combine

Prematurity

Do Not Combine

Sinus Bradycardia

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Propranolol may interact with Pulse Frequency

There are 20 known major drug interactions with Hemangeol.

Common Hemangeol Drug Interactions

Drug Name

Risk Level

Description

4-Bromo-2,5-dimethoxyphenethylamine

Major

The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Propranolol.

4-Methoxyamphetamine

Major

The therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Propranolol.

Abediterol

Major

Propranolol may decrease the bronchodilatory activities of Abediterol.

Adrafinil

Major

The therapeutic efficacy of Adrafinil can be decreased when used in combination with Propranolol.

Agrostis gigantea pollen

Major

The risk of a hypersensitivity reaction to Agrostis gigantea pollen is increased when it is combined with Propranolol.

Hemangeol Toxicity & Overdose Risk

Symptoms of propranolol overdose include low blood pressure, seizures due to low blood sugar, restlessness, and lack of sleep. Asthma sufferers may experience difficulty breathing. If someone overdoses on propranolol, monitor their vital signs, mental status, and blood sugar. Treat low blood pressure with fluids, slow heart rate with atropine and isoproterenol or aminophylline for difficulty breathing. If fluids don't help, try giving glucagon intravenously, followed by catecholamines. Dialysis will not help since propranolol binds to proteins in the blood.

image of a doctor in a lab doing drug, clinical research

Hemangeol Novel Uses: Which Conditions Have a Clinical Trial Featuring Hemangeol?

Currently, 249 active studies are assessing the potential of Hemangeol to ameliorate Migraine, Catecholamines and Hypertensive diseases.

Condition

Clinical Trials

Trial Phases

Atrial Fibrillation

94 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 1, Phase 3, Early Phase 1

Heart Attack

23 Actively Recruiting

Not Applicable, Phase 1, Phase 4, Phase 2, Early Phase 1, Phase 3

Coronary Artery Disease

1 Actively Recruiting

Not Applicable

Chest Pain

2 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Adrenergic Alpha-Antagonists

0 Actively Recruiting

Migraine

51 Actively Recruiting

Phase 4, Not Applicable, Phase 1, Phase 3, Phase 2, Early Phase 1

Hemangioma

0 Actively Recruiting

Gastroesophageal variceal hemorrhage prophylaxis

0 Actively Recruiting

Migraine Disorders

1 Actively Recruiting

Phase 3

Catecholamines

0 Actively Recruiting

Thyroid Crisis

0 Actively Recruiting

Hypertensive disease

27 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Pheochromocytoma

0 Actively Recruiting

Thyrotoxicosis

0 Actively Recruiting

Cardiovascular Mortality

0 Actively Recruiting

Myocardial Infarction

0 Actively Recruiting

Tremor

0 Actively Recruiting

Cardiomyopathy, Hypertrophic

0 Actively Recruiting

Proliferating Infantile Hemangioma

0 Actively Recruiting

Psychomotor Agitation

0 Actively Recruiting

Hemangeol Reviews: What are patients saying about Hemangeol?

4

Patient Review

6/17/2014

Hemangeol for A Feeling of Restlessness with Inability to Sit Still

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about hemangeol

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is HEMANGEOL a beta blocker?

"Hemangeol belongs to a class of drugs that help to regulate heart rate and treat conditions like angina and migraines."

Answered by AI

Is Hemangeol the same as propranolol?

"The medicine propranolol is not able to be removed by dialysis. HEMANGEOL is an oral solution of propranolol that does not contain alcohol, parabens, or sugar. Each mL of HEMANGEOL contains 4.28 mg of propranolol hydrochloride, USP equivalent to 3.75 mg of propranolol."

Answered by AI

How long does it take for Hemangeol to work?

"8 out of 10 babies in this study improved after 5 weeks of using HEMANGEOL with 60% of them seeing complete or nearly complete resolution of their hemangiomas by 6 months."

Answered by AI

What is Hemangeol used for?

"HEMANGEOL is a medication that is used to treat a type of birthmark called an infantile hemangioma. This condition requires treatment with a medication that enters the bloodstream and circulates throughout the body."

Answered by AI

Clinical Trials for Hemangeol

Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Image of Northwestern University in Chicago, United States.

Exercise Program for Atrial Fibrillation and Heart Failure

60 - 99
All Sexes
Chicago, IL

Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) are very common conditions that often occur together and result in worsening symptoms and reduced quality of life (QoL). Limitations being able to participate in activities of daily living is a primary complaint for AF-HFpEF patients, yet effective strategies to address this issue remain limited. While exercise interventions targeting aerobic training (AT) are recommended for patients with AF and HFpEF, unique challenges exist in this patient population who tend to be older. Specifically, many older patients with AF and HFpEF have muscle weakness, sarcopenia and frailty, that can make aerobic-focused exercise difficult and less tolerable. This study proposes that starting with progressive resistance training (PRT) before aerobic exercise may overcome these issues by improving muscle strength, making AT more manageable, and leading to better health outcomes. The goal of this study is to assess whether a sequential exercise program, named 'PREACTIVE' improves how people feel, decrease the amount of symptoms, and their ability to participate in exercise and activities. This study will specifically test a sequenced exercise approach of resistance training followed by aerobic exercise to improve symptoms, and quality of life in AF-HFpEF.

Waitlist Available
Has No Placebo

Northwestern University

Deepika Laddu, PhD

Image of Fort Bend ISD in Sugar Land, United States.

Wellbeing Interventions for Anxiety

10 - 20
All Sexes
Sugar Land, TX

The goal of this clinical trial is to learn if psychology and music based interventions can impact anxiety and overall wellbeing in adolescents enrolled in choral music classes. The main questions it aims to answer are: Do specific psychology and music based breathing interventions impact anxiety and overall wellbeing in adolescents? Do specific psychology and music based performance anxiety reduction interventions impact anxiety and overall wellbeing in adolescents? Do specific psychology and music based emotion regulation interventions impact anxiety and overall wellbeing in adolescents? Researchers will compare results of pre-test data, post-test data, qualitative interviews, and surveys of adult choral directors to see if there is a measurable impact on adolescent anxiety and overall wellbeing. Participants will: * Use box breathing during choral music warm-ups to connect choral breathing to breathing for anxiety reduction * Use "magnify" technique to compare cognitive distortions regarding an upcoming performance that may cause anxiety to the most likely realistic outcome * Use emotion regulation through song lyrics technique to connect lyrics of choral music repertoire to participants experienced emotions

Waitlist Available
Has No Placebo

Fort Bend ISD

Jane Kuehne, PhD

Have you considered Hemangeol clinical trials?

We made a collection of clinical trials featuring Hemangeol, we think they might fit your search criteria.
Go to Trials
Image of Inova Alexandria Hospital in Alexandria, United States.

Heparin Dosing for Blood Clots and Heart Conditions

18+
All Sexes
Alexandria, VA

The goal of this clinical trial study is to test whether a mathematical calculation, using the patient's gender, weight and kidney function, can better predict a patient's heparin goal dose than a flat number of units per patient weight can. Participants will have the first dose of heparin infusion calculated, after which if adjustments are needed, the Hospital's prebuilt table for results driven dosing for this purpose is used. The researchers will compare the time it takes for the participants to get to the desired goal using the patient's information for calculation versus patients in the past who received the medication using the flat rate. The hypothesis is that the patients with enhanced personal data, gender, weight and kidney function, included for the initial dose, will get to their goal lab value sooner and with less chance of delay or overshooting the goal. A quicker time to goal lab value is beneficial to patients in many ways, including earlier treatment of the clot or coronary issue that the patient is experiencing.

Phase 4
Waitlist Available

Inova Alexandria Hospital

Have you considered Hemangeol clinical trials?

We made a collection of clinical trials featuring Hemangeol, we think they might fit your search criteria.
Go to Trials
Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL

This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.

Waitlist Available
Has No Placebo

U Health (+1 Sites)

Ziad Zoghby, M.D., M.B.A.

Biobeat Technologies Ltd.

Image of Johns Hopkins Medicine in Baltimore, United States.

Embolization for Migraine

18 - 80
All Sexes
Baltimore, MD

This study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used in patients with subdural hematomas. The FDA is allowing the use of Onyx in this study. It is thought that by using Onyx to block the middle meningeal arteries, the amount of migraine-causing substances which are released into the brain's bloodstream will be reduced. The company that manufactures Onyx, Medtronic, is providing the supplies for this study. Participants will be in the study for about 8 months after enrolling, including 6 months of follow up after the procedure. The participants will be asked to complete a daily headache diary and continue the participant's regular migraine medications. Participants will also have several clinic visits and be asked to provide blood samples for research.

Waitlist Available
Has No Placebo

Johns Hopkins Medicine

Risheng Xu, MD, PhD

Medtronic

Have you considered Hemangeol clinical trials?

We made a collection of clinical trials featuring Hemangeol, we think they might fit your search criteria.
Go to Trials